Bottega Veneta Olimpia Medium

Merrimack Pharmaceuticals Inc. Completes Enrollment in a Phase 2 Study of MM 121 in Combination With Exemestane in Breast Cancer Pfizer Inc. (PFE) Approves $10 Billion Share Share Buyback Plan

Faces Ownership Showdown, Elan Risks Losing $2 Billion if Royalty Pharma Walks

Merrimack Pharmaceuticals Inc. Bottega Veneta Olimpia Medium Completes Enrollment of Second Cohort in Phase 2 Study Bottega Veneta Backpack Women's

Staying up to date has never been simpler. Sign up for the today!

Merrimack Pharmaceuticals Inc. Phase 1 Research Supports MM 121 Potential for Investigation as Combination With Chemotherapy in Patients With Advanced Solid Tumors Elan Corporation PLC (ELN) Boss Martin Balenciaga Tote Review

CAMBRIDGE, Mass., July 10, Guess Tote Bags Ebay

Merrimack Pharmaceuticals Inc.' Phase 1 Research Supports MM 121 Potential for Investigation as Combination With Chemotherapy in Patients With Advanced Solid Tumors Major VIVUS, Inc. (VVUS) Shareholder to Support Activist's Slate Source

of MM 121 in Non Small Cell Lung Cancer Forest Laboratories, Inc. (FRX) Braces for Third Bout With Icahn

2013 (GLOBE NEWSWIRE) Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced its intention to offer, subject to market and other conditions, $50 million of its common stock and $75 million in aggregate principal amount of its convertible senior notes due 2020 (the "Notes") in concurrent underwritten public offerings pursuant to Merrimack's effective Registration Statement on Form S 3 (File No. 333 186369) (the "Registration Statement").

Merrimack Pharmaceuticals Inc Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes